NCT02316106 is a Phase 2 clinical trial of daratumumab in Multiple Myeloma, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT02316106?

NCT02316106 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT02316106?

Interventions in NCT02316106: daratumumab, daratumumab, daratumumab.

What condition does NCT02316106 study?

NCT02316106 studies Multiple Myeloma.

Is NCT02316106 still recruiting?

NCT02316106 is currently completed. Last updated 27 April 2025.

Last reviewed 2025-04-27 · How we verify

NCT02316106

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Completed Phase 2 Last updated 27 April 2025

What this trial tests

Phase 2 trial testing daratumumab in Multiple Myeloma in 123 participants. Completed in 3 June 2024.

Timeline

20 May 2015

Primary endpoint
2 June 2023

3 June 2024

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	123
Start date	20 May 2015
Primary completion	2 June 2023
Estimated completion	3 June 2024
Sites	57 locations across France, Netherlands, Russia, United Kingdom, Germany, Israel, Canada, Australia

Drugs / interventions tested

daratumumab (daratumumab) — full drug profile →
daratumumab (daratumumab) — full drug profile →
daratumumab (daratumumab) — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, et al · · 2016 · cited 268× · PMID 26864107 · DOI 10.1111/imr.12389
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
Sanchez L, Wang Y, Siegel DS, Wang ML. · · 2016 · cited 127× · PMID 27363983 · DOI 10.1186/s13045-016-0283-0
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Landgren CO, Chari A, Cohen YC, Spencer A, et al · · 2020 · cited 65× · PMID 32024950 · DOI 10.1038/s41375-020-0718-z
A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.
Kazandjian D, Landgren O. · · 2016 · cited 53× · PMID 28061986 · DOI 10.1053/j.seminoncol.2016.10.008
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
Abramson HN. · · 2018 · cited 42× · PMID 30544512 · DOI 10.3390/ijms19123924
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy.
Dima D, Dower J, Comenzo RL, Varga C. · · 2020 · cited 36× · PMID 32904669 · DOI 10.2147/cmar.s212526
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies.
D'Agostino M, Bertamini L, Oliva S, Boccadoro M, et al · · 2019 · cited 32× · PMID 31847174 · DOI 10.3390/cancers11122015
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.
Seckinger A, Hillengass J, Emde M, Beck S, et al · · 2018 · cited 32× · PMID 30079070 · DOI 10.3389/fimmu.2018.01676

Verify or expand the search:

Other trials of daratumumab

Trials testing the same drug.

NCT04827979 — Daratumumab and Belatacept for Desensitization · Phase 1, PHASE2 · active not recruiting
NCT04280328 — Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma · Phase 1 · completed
NCT03068351 — Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced M · Phase 1 · completed
NCT02841033 — Daratumumab for the Treatment of Patients With AL Amyloidosis · Phase 1, PHASE2 · completed

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02316106 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 27 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02316106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing